Adherence to antiretroviral therapy in HIV-infected children in Italy

References

• BALIS , F.M. , PIZZO , P.A. EDDY , J. 1989 . Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection . Journal of Pediatrics , 114 : 880 – 884 .
   PubMed Web of Science ®Google Scholar
• BESCH , C.L. 1995 . Compliance in clinical trials . AIDS , 9 : 1 – 10 .
   PubMed Web of Science ®Google Scholar
• CAMERON , W. Combining protease inhibitors for optimal HIV therapy . Sixth European Conference on Clinical Aspects and Treatment of HIV infection . Hamburg .
   Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) . 1994 . 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age . Morbidity Mortality Weekly Report , 43 : 1 – 10 .
   Google Scholar
• GUARINO , A. , ALBANO , F. , CASTALDO , A. , SPAGNUOLO , M.I. and BERNI CANANI , R. 1998 . Intestinal malabsorption and zidovudine bioavailability . Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology , 18 : 91 – 92 .
   PubMedGoogle Scholar
• JAPOUR , A. Future aspects in protease inhibitor therapy . Sixth European Conference on Clinical Aspects and Treatment of HIV infection . Hamburg .
   Google Scholar
• MCKINNEY , R.E. , MAHA , M.A. CONNOR , E.M. 1991 . A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease . New England Journal of Medicine , 324 : 1018 – 1025 .
   PubMed Web of Science ®Google Scholar
• MITSUYA , H. , WENWOOD , K.J. FURMAN , P.A. 1985 . 3'-Azido-3'-deoxythymidine (BW A509U): a new antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotrophic virus type II/lymphoadenopathy-associated virus in vitro . Proceedings of the National Academy Sciences, USA , 82 : 7096 – 7100 .
   PubMed Web of Science ®Google Scholar
• MONTANER , J.S.G. , RABOUD , J.M. and RAE , S . FOR THE INCAS AND AVANTI STUDY GROUPS (1998a). Adherence to treatment increases duration of virological suppression regardless of pVL nadir . Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy . September , San Diego , CA . (abstract 191)
   Google Scholar
• MONTANER , J.S.G. , HOGG , R. , RABOUD , J. , HARRIGAN , R. and O'SHAUGHNESSY , M. 1998b . Antiretroviral treatment in 1998 . Lancet , 352 : 1919 – 1922 .
   PubMed Web of Science ®Google Scholar
• SINGH , N. , SQUIER , C. , SIVEK , C. , WAGENER , M. , NGUYEN , M.H. and YU , V.L. 1996 . Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance . AIDS Care , 8 : 261 – 269 .
   PubMed Web of Science ®Google Scholar
• TUDOR-WILLIAMS , G. , ST CLAIR , M.H. McKINNEY , R.E. 1992 . HIV-1 sensitivity to zidovudine and clinical outcome in children . Lancet , 339 : 15 – 19 .
   PubMed Web of Science ®Google Scholar